Health Care & Life Sciences » Biotechnology | Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

Regulus Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
104.84 M
Public Float
75.27 M
Regulus Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$4.03
Market Cap
$27.41 M
Shares Outstanding
20.55 M
Public Float
5.88 M

Profile

Address
10628 Science Center Drive
San Diego California 92121
United States
Employees -
Website http://www.regulusrx.com
Updated 07/08/2019
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Financials

View All

Joseph P. Hagan
President, Chief Executive Officer & Director
Stelios B. Papadopoulos
Chairman